Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Endocrine 2Thoracic 1Sarcoma 1NET 1Gynecologic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 41Colorectal Neoplasms 15Lung Neoplasms 12Ovarian Neoplasms 6Stomach Neoplasms 5Pancreatic Neoplasms 5Neoplasms 5Rectal Neoplasms 4Neoplasm Metastasis 4Melanoma 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Recurrence 3Mesothelioma 3Carcinoma, Pancreatic Ductal 3Peritoneal Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Breast Neoplasms 2Vipoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Spinocerebellar Degenerations 1Somatostatinoma 1Skin Neoplasms 1

Interventions

Trastuzumab 2vatalanib 1tipifarnib 1temsirolimus 1pentetreotide 1Vinorelbine 1Thalidomide 1Sirolimus 1Oxaliplatin 1Leucovorin 1Interleukin-12 Subunit p35 1Interleukin-12 1High-Energy Shock Waves 1Fluorouracil 1Fentanyl 1Everolimus 1Bevacizumab 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Islet Cell × Oxaliplatin × Thoracic × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡